US 12,071,391 B2
Methods for making and using endoxifen
Steven C. Quay, Seattle, WA (US); Yao-Lin Sun, Tainan (TW); LungHu Wang, Kaohsiung (TW); ChangJung Wu, Kaohsiung (TW); and ChuanDer Huang, Tainan (TW)
Assigned to ATOSSA THERAPEUTICS, INC., Seattle, WA (US)
Filed by Atossa Therapeutics, Inc., Seattle, WA (US)
Filed on Mar. 30, 2023, as Appl. No. 18/128,536.
Application 18/128,536 is a continuation of application No. 18/090,757, filed on Dec. 29, 2022, granted, now 11,680,036.
Application 18/090,757 is a continuation of application No. 17/580,428, filed on Jan. 20, 2022, granted, now 11,572,334, issued on Feb. 7, 2023.
Application 17/580,428 is a continuation of application No. 16/641,985, granted, now 11,261,151, issued on Mar. 1, 2022, previously published as PCT/US2018/050272, filed on Sep. 10, 2018.
Claims priority of provisional application 62/693,885, filed on Jul. 3, 2018.
Claims priority of provisional application 62/624,787, filed on Jan. 31, 2018.
Claims priority of provisional application 62/556,884, filed on Sep. 11, 2017.
Claims priority of provisional application 62/556,799, filed on Sep. 11, 2017.
Prior Publication US 2023/0365490 A1, Nov. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/135 (2006.01); C07C 213/10 (2006.01); C07C 217/18 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01)
CPC C07C 217/18 (2013.01) [C07C 213/10 (2013.01); A61K 9/0053 (2013.01); A61K 45/06 (2013.01); C07B 2200/13 (2013.01)] 44 Claims
 
1. A composition comprising an endoxifen and an enteric material,
wherein:
the endoxifen comprises a compound of Formula (III):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and
at least 90% by weight of the compound of Formula (III) is (Z)-endoxifen.